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Emergence of vancomycin resistance during therapy against 
methicillin-resistant Staphylococcus aureus in a burn 
patient- importance of low-level resistance to vancomycin 
Isao Haraga, (Lo) Shuichi Nomura, t3) Shigeru Fukamachi,t4) Hiroyuki Ohjimi,c2) Hideaki Hanaki,c5) 
Keiichi Hiramatsu(5) and Ariaki Nagayama@) 
Objectives: StaphyZococcus aureus with low-level resistance to vancomycin (VLSA) which could develop into 
vancomycin-resistant S. aureus (VRSA) is most important. However, VLSA is difficult to detect by standard 
laboratory methods. We describe here improved methods to detect VLSA. 
Methods: Three methicillin-resistant S. aureus (MRSA) strains, designated Fu6, FulO, and Fu18, were sequentially 
isolated from the burn wound site of a patient, during vancomycin therapy. The properties of these strains were 
compared with those of reference strains Mu3 and Mu.50 (previous resistant isolates from other patients). 
Results: The isolated strains, FulO and Fu18, had identical phenotypes and genotypes. The vancomycin resistance of 
FulO was equivalent to that of strain Mu3, whereas Fu18 had much higher vancomycin resistance than FulO and 
Mu3, although reaching the level of Mu50. Fu18 showed similar growth to Mu50 on gradient gels and on Mu3 
medium. 
Conclusions: Our data indicate that the VLSA developed vancomycin resistance during exposure to vancomycin in 
vivo. The population analysis of tested VLSA and vancomycin intermediately resistant S. aureus (VISA) indicates 
that a penem at relatively low concentrations induced a significant increase in the number of vancomycin-resistant 
subpopulations. Furthermore, we confirmed that gradient gel analysis and Mu3 medium are simple and useful 
methods for the detection of VLSA judged as VSSA by its conventional MIC alone. 
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INTRODUCTION 
The increase in methicillin-resistant Staphylococcus 
uureus (MRSA) infections in hospitals is of global 
c0ncern.i” In Japan, vancomycin, which is believed to 
be the most effective antibiotic against MRSA, has been 
widely used for the treatment of MRSA infections since 
1991. However, vancomycin therapeutic failures have 
occasionally occurred in spite of the low MIC values 
of vancomycin for the isolated MRSA strains. The first 
strains of vancomycin-resistant S uureus (VRSA), 
Mu50, and heterogeneous VRSA (hetero-VRSA), Mu3, 
were reported in 1997. 1,4 Thereafter, isolates of VRSA- 
like Mu50 were reported from different geographic 
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areas, including the USA and France.5-‘o Vancomycin- 
susceptible strains (VSSA) have MICs of 2 u,g/mL or 
less, and are completely inhibited by 4 kg/mL of vanco- 
mycin.’ VRSA was defined as S. uureus with an MIC 
for vancomycin of 8 pg/mL or above by the NCCLS 
method.‘,*l It is equivalent to VISA (vancomycin 
intermediately resistant S. aureus )5,6,11 or GISA (glyco- 
peptide intermediately resistant S. aureus).l’ Hetero- 
VRSA was defined as S. uureus that gave lOA or more 
colonies in the presence of 8 kg/mL of vancomycin 
by Hiramatsu and co-workers;l,l’ that is, hetero-VRSA 
is synonymous with an S. uureus strain with low-level 
resistance to vancomycin (VLSA).12 Therefore, we use 
this term instead of hetero-VRSA in this paper. In the 
case of extensive burn patients, MRSA wound infection 
can often not be eliminated, despite intensive vanco- 
mycin therapy. Vancomycin therapeutic failure in 
MRSA wound infections has been largely attributed to 
the poor status of such patients (defect of skin, 
malnutrition, loss and imbalance of electrolytes, de- 
creased neutrophil number, etc.). Furthermore, some 
VLSA isolates from a patient that are judged to be 
VSSA according to the NCCLS criteria may cause 
vancomycin therapeutic failure. During vancomycin 
therapy of a burn patient with an MRSA wound infec- 
tion, we recovered sequentially three MRSA wound 
isolates. 
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We describe here the properties of these MRSA 
isolates, showing increases in their vancomycin resis- 
tance in vivo on exposure to vancomycin, and we would 
like to emphasize the importance of VLSA judged as 
VSSA by conventional MIC alone. 
MATERIALS AND METHODS 
Patients 
A 2-year-old male with a body weight of 12 kg was 
admitted to our Intensive Care Unit on 18 January 1998 
after sustaining flame burns to his face, chest, abdomen, 
back, and left upper extremities (20% of his total body 
surface area; Burn Index 15). On hospital day 1, wound 
cultures revealed no MRSA, but to prevent infection, 
the patient was given intravenous piperacillin. On 
hospital day 10, cultures from the wound were positive 
for MRSA (designated as Fu6). The patient’s temper- 
ature was 40°C and the C-reactive protein (CRP) level 
was 25.6 mg/dL. The patient was treated with gentamicin 
(0.8 mg/kg daily). On hospital day 16, fever continued 
(39”Q but the CRP had declined to 3.4 mg/dL. On 
hospital day 19, gentamicin was discontinued in favor of 
vancomycin (20.8 mglkg, IV, every 12 h). On hospital day 
21, the fever continued (41°C) and the CRP had risen 
to 14 mg/dL. Therefore, on hospital day 22, the treat- 
ment was changed to a combination of vancomycin 
(20.8 mg/kg, IV, every 12 h) and imipenem (62.5 mgfkg, 
IV, every 12 h). On hospital day 27, cultures from the 
wound were positive for gentamicin-resistant, arbekacin- 
susceptible and vancomycin-susceptible MRSA (desig- 
nated as FulO), as judged from the sensitivity disk test. 
On hospital day 30, although fever continued (38.5”Q 
the CRP declined to 2.3 mg/dL. On hospital day 35, as 
the patient’s temperature again rose to 40°C vanco- 
mycin and imipenem were discontinued in favor of 
arbekacin (4.2 mg/kg, IV, every 24 h) and sulbactam- 
ampicillin (62.5 mg/kg, IV, every 12 h). After this, there 
was a downward trend in the fever for 9 days ; however, 
on hospital day 44, it rose again to 39°C and wound 
cultures were positive for MRSA (designated as Fu18) 
again. Therefore, therapy with arbekacin and sulbactam- 
ampicillin was changed to every 12 h. On hospital day 
51, the patient’s fever had subsided (36.5”C), and the 
CRP declined to 0.3 mg/dL. Finally, MRSA disappeared, 
and the patient was cured and discharged. The case 
summary is shown in Figure 1. 
Bacterial strains 
Fu6, FulO and Fu18 were wound isolates of MRSA 
obtained on hospital days 10, 27 and 44, respectively. 
Mu50 and Mu3 have been described previously.1,4 
FDA209P (ATCC6538P) a reference strain of S. aureus, 
was purchased from the Japanese National Institute of 
Health and Disease Prevention. 
Detection of vancomycin-resistant S. aureus on Mu3 
medium 
Mu3 medium13,i4 (Nippon Becton Dickinson Co., Ltd, 
Tokyo, Japan), and modified brain heart infusion (BHI) 
agar medium supplemented with 4 mg vancomycin/mL, 
were inoculated with tested strains. After several disks 
impregnated with B-lactams (imipenem O.Ol,O.l, 1.0 and 
10 Fg/mL) had been placed on the agar, the plates were 
incubated at 37°C for 24 h. 
Genotyping 
The comparison of genetic traits of clinical isolates Fu6, 
FulO and Fu18 with those of Mu3, Mu50 and FDA209P 
(MSSA) was done by pulsed-field gel electrophoresis 
(PFGE).15 PFGE patterns were interpreted according to 
the established criteria.16 
Phenotyping and susceptibility tests 
The biotypes were determined by use of Api Staph Trac 
from BioMerieux, Tokyo, Japan. The coagulase typing, 
enterotoxin typing and test for toxic shock syndrome 
toxin-l (TSST-1) production were performed with com- 
mercially available kits from Dennka Seiken, Tokyo, 
Japan. 
MICs were determined by use of BHI agar plates 
(Difco, Becton Dickinson Co., Sparks, MD, USA) and 5- 
mL spot inoculum of cell suspension (10’ CFU/mL) 
according to the NCCLS method.” Unless otherwise 
stated, the MIC was defined as the minimum concen- 
tration of antibiotic needed to inhibit the growth of 
5~ lo4 CFU after 16 h of incubation at 37°C. Methicillin 
(Sigma Aldrich Japan, Co., Tokyo, Japan), vancomycin 
(Sigma Aldrich Japan), teicoplanin (Hoechst-Marion- 
Roussel Ltd,Tokyo, Japan), arbekacin (Meiji Seika Ltd, 
Tokyo, Japan), gentamicin (Sigma Aldrich Japan), imi- 
penem (Banyu Pharmaceutical Co., Ltd, Tokyo, Japan), 
cefpirome (Hoechst-Marion-Roussel), sulbactam- 
ampicillin (Pfizer Pharmaceutical Inc., Tokyo, Japan), 
piperacillin (Toyama Chemical Co., Ltd, Tokyo, Japan) 
and oxacillin (Sigma Aldrich Japan) were tested. 
Gradient gel analysis 
FulO, Fu18, Mu3, Mu50 and FDA209P were grown in 
BHI broth at 37°C with shaking. A suspension of 
2.5~10~ cells/ml of an overnight culture was streaked 
onto defined BHI agar plates containing gradients of 
vancomycin.i8 
Population analysis 
Population analysis was done according to the method 
described by Berger-Bachi et a1.i9 Briefly, 100 mL of the 
starting cell suspension (prepared by diluting overnight 
cultures to an OD578 of 0.3) and its serial diluents were 
spread over BHI agar plates containing various concen- 
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Temperature 
41 
39 
37 
r I 35 
Days 1 10 19 27 35 44 51 
CRP 0.5 25.6 8.1 
PIPC 0.2glkg GM 0.83glkg VCM 20.8mglkg ABK 4.2mglkg ABK 2.5mglkg 
Antibiotics every 8h every 24h every 12h every 24h every 12h 
CPR 0.16glkg IPMlCS 62.5mglkg 
every 24h every 12h 
SJ$y2\C 62.5mglkg 
Disk placement* 
FDA209P Mu3 Mu50 
Figure 1. Course of medical treatment and detection of VLSA on Mu3 medium. 1, 10 kg/mL imipenem; 2, 1 pg/mL imipenem; 3, 
0.1 uo/mL imioenem; 4, 0.01 r.w/mL imipenem. PIPC, piperacillin; GM, gentamicin; CPR, cefpirome; VCM, vancomycin; IPM, imipenem; 
ASK, arbekacin; SBT/ABbC, suib&tam-ampicillin. 
trations of vancomycin. The number of colonies was 
counted after 48 h of incubation at 37°C and then 
plotted on a semi-logarithmic graph.’ 
RESULTS 
Emergence of vancomycin-resistant S. aweus during 
vancomycin treatment as detected by use of Mu3 
medium 
The course of medical treatment and growth patterns of 
the six tested strains on Mu3 medium are shown in 
Figure 1. FDA209P and Fu6 obtained before vanco- 
mycin treatment showed essentially no growth at all on 
Mu3 medium. FulO isolated after 7 days of vancomycin 
treatment showed a similar growth zone around the p- 
lactam disks as Mu3. Fu18 isolated after a total of 16 
days of vancomycin treatment and then during the 
course of arbekacin and sulbactam-ampicillin treatment 
grew all over the surface on Mu3 medium. This growth 
pattern was almost the same as that of Mu.50. 
Genotype 
PFGE banding patterns of Fu6, FulO, Fu18, Mu3, Mu50 
and FDA209P are shown in Figure 2. FulO and Fu18 had 
identical PFGE banding patterns. The pattern was 
similar to that of Mu3 and Mu50, representative of the 
MRSA clonotype II-A, with two band differences 
(arrows). By contrast, these strains had banding patterns 
different from those of the other strains (Fu6 and 
FDA209P). 
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Figure 2. Pulsed-field gel electrophoresis banding patterns 
of Fu 6, FulO, Fu18, Mu3, Mu50, and FDA209P MWM is the 
molecular weight marker (concatemer of lambda-phage DNA). 
Phenotype and MICs 
The properties of these strains are shown in Table 1. 
Whereas strain Fu6 showed phenotypic differences in 
biotype and enterotoxin type, the other four strains 
(FulO, Fu18, Mu3, Mu50) were identical by conventional 
phenotyping assays, including biotype, coagulase type, 
TSST-1 production, and enterotoxin type. MICs of 
vancomycin for Fu6 and FulO remained the same as 
that of Mu3 (2 kg/mL). The observed MIC difference 
between FulO and Fu18 was increased vancomycin 
Table 1. Properties of MRSA strains 
resistance in the latter, although not to the level of 
Mu50. In addition to vancomycin resistance, Fu18 had 
increased resistance to teicoplanin and arbekacin. 
Gradient gel analysis 
Figure 3 shows a comparison of the gradient gel analysis 
of serial isolates FulO and Fu18 described above with 
that of Mu3, Mu50, and FDA209l? The vancomycin 
resistance of FulO was equivalent to that of Mu3. Fu18 
showed greater vancomycin resistance than FulO and 
Mu3, almost the same as Mu50. The growth patterns of 
these strains on gradient gel represent vancomycin 
resistance. Although Mu3, FulO and Fu18 contained 
small resistant populations that grew in the presence of 
4 yg/mL of vancomycin, MICs of these strains were 
2-4 pg/mL. Therefore, VLSA strains cannot be 
discriminated from VSSA strains by MIC values alone. 
From this point of view, population analysis and gradient 
gel analysis are useful for detecting VLSA. 
0 vancomycin (kg/ml) 4 
Figure 3. Gradient gel analysis. Growth of different 5. aureus 
strains at 37°C for 24 h on defined BHI agar plates containing a 
gradient of vancomycin: lane 1, Mu50; lane 2, Mu3; lane 3, 
FDA209P; lane 4, FulO; lane 5, Fu18. ’ 
Minimum inhibitory concentrations 
Coagulase Tsst- 1 En tero toxin (MiCs, ~glml) 
Strains Biotype type production We DMPPC VCM TEIC ABK GM IPM CPR SBTIABPC PIPC 
Fu6 6336153 II + C >I28 2 4 0.5 0.5 32 32 16 64 
FulO 6736153 II + AC >I28 2 8 8 2128 128 128 32 >I28 
Fu18 6736153 II + AC >I28 4 16 16 >128 128 128 32 >I28 
Mu3 6736153 II + AC >128 2 16 4 >I28 128 128 32 >I28 
Mu50 6736153 II + AC >I28 8 16 8 >I28 64 64 32 2128 
FDA209P ND ND ND ND 2 1 0.5 0.5 0.5 0.5 1 0.5 1 
ND: Not determined. 
MICs: lnoculum size was 5x lo4 CFWspot (5 &pot with 1 x lo7 CFWml). 
DMPPC: methicillin, VCM: vancomycin, TEIC: teicoplanin, ABK: arbekacin, GM: gentamicin. 
IPM/CS: imipenem/cilastatin, CPR: cefpirome, SBT/ABPC: sulbactamlampicillin, PIPC: piperacillin. 
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Effects of combinations of p-lactam and 
vancomycin on vancomycin-resistant MRSA 
Sieradzki et al showed that the combinations of /3-lactam 
antibiotics and vancomycin were highly effective against 
their isolate of VRSA,‘O and noted that it should be 
determined whether this combination of antibiotics is 
effective against other VRSA isolates. Thereafter, Climo 
et al described the evidence that combinations of 
vancomycin and p-lactams were synergistic in vitro and 
(4 
01234567 8 9 10 
Vancomycin (wg/ml) 
01234567 a 9 IO 01234567 8 9 10 
Vancomycin (kg/ml) Vancomycin (kg/ml) 
also in an in vivo endocarditis model against vancomycin- 
resistant S. aureus.2o We have often observed a growth 
zone around the p-lactam disks on Mu3 medium plates 
containing vancomycin at 4 &mL. On the basis of these 
findings, we have already reported the effectiveness of 
vancomycin against VLSA strains in combination with 
various concentrations of /3-lactams.12 Furthermore, we 
here found similar effects on VLSA with a combination 
of vancomycin and a penem. Figure 4 shows the effects of 
a combination of vancomycin and imipenem on Mu3, 
108 
106 
g IO4 
8 
102 
0 
108 
106 
E 
5 104 
b 
102 
0 
W 
01234567 8 9 10 
Vancomycin (*g/ml) 
PI 
Figure 4. Enhancement or inhibition of the vancomycin-resistant strains, Mu3 (A), FulO (B), FulB (C), and Mu50 (D), by 
a combination of vancomycin and imipenem. Overnight cultures of Mu3, FulO, FulB and Mu50 were plated at different cell 
concentrations on three sets of BHI agar plates: the first set contained various concentrations of vancomycin (0), the second set 
contained the same concentrations of vancomycin as well as a lower concentration of imipenem (0.05 pglmL)(n), and the third 
set contained the same concentrations of vancomycin with a higher concentration of imipenem (2.0 pg/mL)(V). The arrow in (C) 
indicates the antagonistic effect on vancomycin resistance of a low concentration of imipenem (4.0 WglmL). 
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FulO, Fu18, and Mu50 respectively. The population 
analysis indicates that imipenem at a relatively high 
concentration of 2 p,g/mL, which is l/8 to l/64 of the MIC 
values, induced a reduction in the number of subpopula- 
tions resistant to vancomycin. However, at relatively 
lower imipenem concentrations of 0.05-0.2 pg/mL (data 
not shown), the number of surviving colonies increased as 
expected; for example, with 4 kg/mL of vancomycin 
together with 0.05 p,g/mL of imipenem, surviving colonies 
of Fu18 were about one hundred times those found with 
the use of vancomycin alone (Figure 4C, arrow). 
DISCUSSION 
We have reported here a case of a patient with extensive 
burns and described the properties of MRSA strains 
isolated from the burn wound. On hospital day 10, the 
first MRSA strain, Fu 6, sensitive to gentamicin, was 
isolated; this disappeared after treatment with genta- 
micin. On hospital day 22, we isolated another MRSA 
strain, FulO, which was clearly an MRSA strain different 
from Fu6 by biotype, genotype, and antibiotic sensitivity. 
As is shown in Figures 1,3, and 4, FulO was obviously a 
VLSA strain that had properties similar to those of Mu3 
in terms of growth on Mu3 medium, gradient gel pattern, 
and population analysis. On hospital day 44,9 days after 
changing the 16-day vancomycin therapy to arbekacin 
with sulbactam-ampicillin, MRSA strain Fu18 was 
isolated. Fu18 was entirely identical to FulO in terms of 
genotype and phenotype, but differed in having greater 
vancomycin resistance. FulO and Fu18 had identical 
PFGE banding patterns, similar to those of Mu3 and 
Mu50, with only two additional bands. Based on these 
banding patterns, FulO and Fu18 belong to clonotype II- 
A, which is the prominent MRSA clonotype in Japan, 
producing type 2 coagulase andTSST-1 toxin.1,‘1*21 Fu18 
was more resistant to vancomycin than FulO, as indi- 
cated by population analysis. A very small population 
of Fu18 cells grew in 8 p,g/mL of vancomycin, whereas 
FulO and Mu3 did not.12 The growth of Fu18 on Mu3 
medium or on gradient gels also indicated that the 
resistance of Fu18 was much higher than that of FulO 
(Figures 1 and 3). We assume that Fu18 was selected 
from FulO in vivo, during vancomycin treatment, as a 
subclone with vancomycin resistance close to that of 
Mu50. It is surprising that such selection of a resistant 
subclone occurred within 2 weeks. 
The peak tissue concentrations obtained by intra- 
venous vancomycin administration are around 5 bg/mL 
or less (e.g. 5 kg/mL in abscess,22 2.49 pg/mL in sputa23), 
except in the blood of hemodialysis patients or in the 
peritoneal fluid of peritoneal dialysis patients. Therefore, 
it is likely that in a large number of respiratory or wound 
infections, not only VRSA but also VLSA will not be 
eliminated by vancomycin. From these findings, we 
confirmed that vancomycin therapeutic failure against 
VLSA resulted in selection of subclones of VLSA with 
greater vancomycin resistance which then gave rise to 
the emergence of VRSA in vivo. Fortunately, in the case 
of our patient, before the subclone with vancomycin 
resistance equal to that of Mu50 (MIC 8 p&mL) was 
selected, the symptoms were relieved by arbekacin and 
sulbactam-ampicillin combination therapy. 
In our experiments with the combinations of vanco- 
mycin and imipenem, such combinations were effective 
against the VLSA and VISA strains at relatively high 
concentrations of p-lactams, as reported previously.10~12~20 
However, the relatively low concentrations of p-lactams 
affected the resistance of MRSA to vancomycin.12 It 
seems that the activated synthesis and turnover of cell 
walls24 in VLSA may be enhanced by relatively low 
concentrations of p-lactams. When compared with 
vancomycin alone, the resistant subpopulation does 
significantly increase with the combination of p-lactams. 
This is one of the reasons why VLSA showed visible 
growth around p-lactam disks on Mu3 medium. Such 
lower concentrations of p-lactams occur in all tissues or 
plasma during the treatment of patients with antibiotics. 
According to pharmacokinetic studies of imipenem, 
its mean half-life is 54-110 min;25*26 therefore, the peak 
tissue or plasma concentrations of imipenem obtained 
with intravenous administration readily decline with 
time and become undetectable within 8 h. Similar pro- 
cesses occur for all p-lactams. Therefore, one should be 
cautious about using combination therapy of vanco- 
mycin and p-lactams including penems for a patient 
infected with VLSA. 
The VLSA and VISA strains from our present case 
were also resistant to teicoplanin: MIC for FtilO, 
8 kg/mL; MIC for Mu3, Fu18 and Mu50,16 yg/mL. In 
Japan, vancomycin was introduced in 1991, and 
teicoplanin in 1998. It has been reported that S. aureus 
produces teicoplanin-resistant mutants more readily 
than vancomycin-resistant mutants,27 and the resultant 
mutants are cross-resistant to vancomycin.28 Therefore, 
we would like to stress that in the case of VLSA in- 
fection, vancomycin and teicoplanin should be used with 
caution. As Waldvoge129 has pointed out, intermediate 
resistance is difficult to detect by standard laboratory 
methods, and Tabaqchali has emphasized the need to 
improve the methods to detect VLSA and to monitor 
the emergence of VRSA,3 especially in patients un- 
responsive to vancomycin or teicoplanin therapy. There- 
fore, we recommend gradient gel analysis and especially 
Mu3 medium, which are simple and useful for the 
detection of MRSA with low-level vancomycin resist- 
ance. Finally, as seen in Figure 4, population analysis 
profiles showed that not only hetero-VRSA (Mu3) 
but also VISA (Mu50) had heterogeneous resistance 
to vancomycin. To avoid confusion, we proposed and 
used the new term vancomycin low-level resistant S. 
aureus (VLSA), which serves as a precursor for VRSA 
(VISA); VLSA itself can cause vancomycin therapeutic 
failure. 
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